Categories: News

Quantinuum Selected by DARPA to Advance to Stage B of Quantum Benchmarking Initiative

With the industry’s most advanced quantum systems and proven ability to scale, Quantinuum is on track to deliver utility-scale quantum computing by early 2030s

- Advertisement -

BROOMFIELD, Colo., Nov. 6, 2025 /PRNewswire/ — Quantinuum, the world leader in quantum computing, has been selected by the Defense Advanced Research Projects Agency (DARPA) as a contractor to advance to Stage B of DARPA’s Quantum Benchmarking Initiative (QBI).

- Advertisement -

DARPA is using QBI to evaluate the technical likelihood that a utility scale quantum computer will be available no later than 2033. A multi-stage program, Stage B follows a six-month Stage A effort in which Quantinuum developed and delivered a detailed concept design for a utility scale system called “Lumos.”

- Advertisement -

Last year, Quantinuum released its public roadmap through the end of the decade with Apollo—a universal, fully fault-tolerant quantum computer—scheduled for launch in 2029. Lumos is a new addition to the roadmap as Quantinuum outlines plans to develop increasingly larger systems into the 2030s.

- Advertisement -

“This selection recognizes the strength and maturity of our roadmap and the work our teams have already delivered,” said Dr. Rajeeb Hazra, President and CEO of Quantinuum. “Lumos extends our roadmap into the next decade and gives DARPA a concrete, de-risked path for achieving utility-scale quantum computing by 2033. We look forward to partnering with DARPA and our ecosystem partners to advance this important national objective.”

- Advertisement -

Stage B will be a year-long, performance-based evaluation by DARPA’s Test and Evaluation team in which Quantinuum will develop a detailed R&D roadmap for Lumos to validate technical assumptions, verification methods, and scaling plans to meet the 2033 objective.

- Advertisement -

Yesterday, Quantinuum deployed its latest generation system, “Helios,” on schedule with its roadmap. With the highest fidelity physical qubits and logical qubits of any commercial system, and a next-generation software stack featuring a modern, high-level programming language, Helios is designed to accelerate quantum computing adoption. The system has already been used to simulate high-temperature superconductivity and magnetism at unprecedented scales—two applications with relevance to critical, industrial utility.  

- Advertisement -

About Quantinuum

- Advertisement -

Quantinuum is the world leader in quantum computing. The company’s quantum systems deliver the highest performance across all industry benchmarks. Quantinuum’s over 630 employees, including 370+ scientists and engineers, across the US, UK, Germany, and Japan, are driving the quantum computing revolution. 

- Advertisement -

For more information, please visit www.quantinuum.com

- Advertisement -

Logo: https://mma.prnewswire.com/media/2655950/5607877/Quantinuum_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/quantinuum-selected-by-darpa-to-advance-to-stage-b-of-quantum-benchmarking-initiative-302607933.html

- Advertisement -

Recent Posts

Deepak Group Goes Beyond Green with hands-On Mangrove Restoration

Deepak Group undertakes mangrove plantation drive on World Environment DaySustainable restoration along the Paniyadra coast,…

4 hours ago

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

8 hours ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

8 hours ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

8 hours ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

8 hours ago